Approximately 75% of breast cancers rely on ER signaling to grow and survive.2 Endocrine therapy, which blocks the growth-promoting activity of estrogen, represents the primary intervention for early- and advanced-stage ER-positive breast cancer.3 However, some patients do not respond to endocrine therapy (ie, de novo resistance), and some patients who initially respond to therapy have disease that progresses during therapy (ie, acquired resistance).3

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) that has undergone a major evolution over the past decade.

Results 1 - 2 of 2